172 related articles for article (PubMed ID: 15734863)
1. N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice.
Shibuya K; Kanasaki K; Isono M; Sato H; Omata M; Sugimoto T; Araki S; Isshiki K; Kashiwagi A; Haneda M; Koya D
Diabetes; 2005 Mar; 54(3):838-45. PubMed ID: 15734863
[TBL] [Abstract][Full Text] [Related]
2. N-Acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells.
Kanasaki K; Koya D; Sugimoto T; Isono M; Kashiwagi A; Haneda M
J Am Soc Nephrol; 2003 Apr; 14(4):863-72. PubMed ID: 12660320
[TBL] [Abstract][Full Text] [Related]
3. Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
Castoldi G; di Gioia CR; Bombardi C; Preziuso C; Leopizzi M; Maestroni S; Corradi B; Zerbini G; Stella A
Am J Nephrol; 2013; 37(1):65-73. PubMed ID: 23327833
[TBL] [Abstract][Full Text] [Related]
4. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.
Ziyadeh FN; Hoffman BB; Han DC; Iglesias-De La Cruz MC; Hong SW; Isono M; Chen S; McGowan TA; Sharma K
Proc Natl Acad Sci U S A; 2000 Jul; 97(14):8015-20. PubMed ID: 10859350
[TBL] [Abstract][Full Text] [Related]
5. N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis.
Omata M; Taniguchi H; Koya D; Kanasaki K; Sho R; Kato Y; Kojima R; Haneda M; Inomata N
J Am Soc Nephrol; 2006 Mar; 17(3):674-85. PubMed ID: 16452498
[TBL] [Abstract][Full Text] [Related]
6. Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
Castoldi G; di Gioia CR; Bombardi C; Perego C; Perego L; Mancini M; Leopizzi M; Corradi B; Perlini S; Zerbini G; Stella A
Clin Sci (Lond); 2009 Oct; 118(3):211-20. PubMed ID: 20310083
[TBL] [Abstract][Full Text] [Related]
7. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse.
Hong SW; Isono M; Chen S; Iglesias-De La Cruz MC; Han DC; Ziyadeh FN
Am J Pathol; 2001 May; 158(5):1653-63. PubMed ID: 11337363
[TBL] [Abstract][Full Text] [Related]
8. Investigating the antifibrotic potential of N-acetyl seryl-aspartyl-lysyl-proline sequence peptides.
Ramasamy V; Ntsekhe M; Sturrock E
Clin Exp Pharmacol Physiol; 2021 Nov; 48(11):1558-1565. PubMed ID: 34347311
[TBL] [Abstract][Full Text] [Related]
9. N-acetyl-seryl-aspartyl-lysyl-proline mediates the anti-fibrotic properties of captopril in unilateral ureteric obstructed BALB/C mice.
Chan GCW; Wu HJ; Chan KW; Yiu WH; Zou A; Huang XR; Lan HY; Lai KN; Tang SCW
Nephrology (Carlton); 2018 Apr; 23(4):297-307. PubMed ID: 28075040
[TBL] [Abstract][Full Text] [Related]
10. N-acetyl-seryl-aspartyl-lysyl-proline inhibits DNA synthesis in human mesangial cells via up-regulation of cell cycle modulators.
Kanasaki K; Haneda M; Sugimoto T; Shibuya K; Isono M; Isshiki K; Araki S; Uzu T; Kashiwagi A; Koya D
Biochem Biophys Res Commun; 2006 Apr; 342(3):758-65. PubMed ID: 16497271
[TBL] [Abstract][Full Text] [Related]
11. Renal protective effect of N-acetyl-seryl-aspartyl-lysyl-proline in dahl salt-sensitive rats.
Worou ME; Liao TD; D'Ambrosio M; Nakagawa P; Janic B; Peterson EL; Rhaleb NE; Carretero OA
Hypertension; 2015 Oct; 66(4):816-22. PubMed ID: 26324505
[TBL] [Abstract][Full Text] [Related]
12. Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats.
Peng H; Carretero OA; Raij L; Yang F; Kapke A; Rhaleb NE
Hypertension; 2001 Feb; 37(2 Pt 2):794-800. PubMed ID: 11230375
[TBL] [Abstract][Full Text] [Related]
13. Interaction of N-acetyl-seryl-aspartyl-lysyl-proline with the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis attenuates pulmonary fibrosis in silicotic rats.
Gao X; Xu H; Zhang B; Tao T; Liu Y; Xu D; Cai W; Wei Z; Li S; Zhang H; Mao N; Zhang G; Li D; Jin F; Li S; Zhang L; Liu H; Hao X; Yang F
Exp Physiol; 2019 Oct; 104(10):1562-1574. PubMed ID: 31290182
[TBL] [Abstract][Full Text] [Related]
14. Ac-SDKP ameliorates the progression of lupus nephritis in MRL/lpr mice.
Tan H; Zhao J; Wang S; Zhang L; Wang H; Huang B; Liang Y; Yu X; Yang N
Int Immunopharmacol; 2012 Dec; 14(4):401-9. PubMed ID: 22922317
[TBL] [Abstract][Full Text] [Related]
15. N-Acetyl-Seryl-Aspartyl-Lysyl-Proline: mechanisms of renal protection in mouse model of systemic lupus erythematosus.
Liao TD; Nakagawa P; Janic B; D'Ambrosio M; Worou ME; Peterson EL; Rhaleb NE; Yang XP; Carretero OA
Am J Physiol Renal Physiol; 2015 May; 308(10):F1146-54. PubMed ID: 25740596
[TBL] [Abstract][Full Text] [Related]
16. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin.
Liu YH; D'Ambrosio M; Liao TD; Peng H; Rhaleb NE; Sharma U; André S; Gabius HJ; Carretero OA
Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H404-12. PubMed ID: 19098114
[TBL] [Abstract][Full Text] [Related]
17. N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research.
Liao TD; Yang XP; D'Ambrosio M; Zhang Y; Rhaleb NE; Carretero OA
Hypertension; 2010 Feb; 55(2):459-67. PubMed ID: 20026760
[TBL] [Abstract][Full Text] [Related]
18. New anti-fibrotic mechanisms of n-acetyl-seryl-aspartyl-lysyl-proline in silicon dioxide-induced silicosis.
Sun Y; Yang F; Yan J; Li Q; Wei Z; Feng H; Wang R; Zhang L; Zhang X
Life Sci; 2010 Aug; 87(7-8):232-9. PubMed ID: 20624403
[TBL] [Abstract][Full Text] [Related]
19. The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis.
Mnguni AT; Engel ME; Borkum MS; Mayosi BM
PLoS One; 2015; 10(12):e0143338. PubMed ID: 26656271
[TBL] [Abstract][Full Text] [Related]
20. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria.
Wang A; Ziyadeh FN; Lee EY; Pyagay PE; Sung SH; Sheardown SA; Laping NJ; Chen S
Am J Physiol Renal Physiol; 2007 Nov; 293(5):F1657-65. PubMed ID: 17804483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
